SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Sodium chloride 0.9% and potassium chloride 0.3% in plastic container provides isotonic crystalloid solution for resuscitation and maintenance of extracellular fluid volume. Sodium chloride restores sodium and chloride deficits, while potassium chloride replenishes potassium, essential for maintaining cellular membrane potential, nerve conduction, and muscle contraction, including cardiac function.
| Metabolism | Not metabolized; sodium and potassium are excreted primarily by the kidneys. |
| Excretion | Renal: >95% as chloride and sodium ions; potassium ions also excreted renally (90% reabsorbed, remainder excreted). Biliary/fecal: negligible (<5%). |
| Half-life | Sodium and chloride: 6–12 hours (tissue distribution equilibrium); potassium: 12–24 hours (slow exchange from intracellular stores). Clinical context: half-life prolonged in renal impairment. |
| Protein binding | Sodium, chloride, potassium: not protein bound (0% binding). |
| Volume of Distribution | Sodium/chloride: 0.15–0.25 L/kg (extracellular fluid); potassium: 4–5 L/kg (total body water, with preferential intracellular distribution). Clinical meaning: sodium distributes mainly in plasma and interstitial fluid; potassium distributes extensively into cells. |
| Bioavailability | Intravenous: 100%. Not administered orally; enteral absorption would be 100% but is not a relevant route for this formulation. |
| Onset of Action | Intravenous: immediate (within minutes) for electrolyte repletion; effects on hydration occur within 1–2 hours. |
| Duration of Action | Intravenous: 2–4 hours for electrolyte balance; hydration effects last 24–48 hours depending on renal function and losses. |
| Molecular Weight | 58.44 |
Intravenous infusion, rate and volume determined by clinical need: typical adult dose is 1-2 L/day for maintenance or replacement, up to 3-4 L/day for deficits; maximum infusion rate 1 L/hour under continuous monitoring. Contains 0.9% sodium chloride (154 mEq/L Na+, Cl-) and 0.3% potassium chloride (40 mEq/L K+).
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in anuria or severe renal impairment (GFR <30 mL/min) due to risk of hyperkalemia and fluid overload. For GFR 30-60 mL/min, use with caution, monitor serum potassium and renal function; reduce infusion rate by 50% if required. In acute kidney injury, avoid use unless guided by serum electrolytes. |
| Liver impairment | No specific dose adjustment for Child-Pugh A or B; use cautiously in Child-Pugh C due to risk of fluid overload and electrolyte disturbances. Monitor potassium levels closely, as hepatic impairment may affect potassium regulation. |
| Pediatric use | Weight-based: infants and children: maintenance 100-120 mL/kg/day for first 10 kg, plus 50 mL/kg/day for next 10 kg, plus 20 mL/kg/day for each additional kg; for deficits, replace based on losses. Maximum rate 10 mL/kg/hour (but limited by potassium content to 0.5 mEq/kg/hour). Use only if potassium deficit confirmed and renal function normal. |
| Geriatric use | Use with caution due to age-related renal impairment and fluid overload risk. Initiate at lower rates (e.g., 1 mL/kg/hour) and titrate based on clinical and electrolyte monitoring. Monitor serum potassium closely as hyperkalemia is more common. Reduce total daily volume by 30-50% in patients with congestive heart failure or chronic kidney disease. |
| 1st trimester | No known teratogenic effects; use for electrolyte replacement as needed. |
| 2nd trimester | Safe for electrolyte repletion; monitor serum potassium and sodium. |
| 3rd trimester | Safe; avoid excess potassium to prevent neonatal hyperkalemia. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Sodium and potassium actively transport across the placenta to maintain fetal electrolyte homeostasis; administration of physiologic replacement doses does not result in significant fetal exposure beyond normal physiological levels. |
| Breastfeeding | Both sodium and potassium are normal constituents of breast milk and are not expected to cause adverse effects in the nursing infant when used at therapeutic doses. However, high concentrations or large volumes may alter milk electrolyte composition; monitoring of infant serum electrolytes is not routinely required unless maternal levels are markedly abnormal. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Sodium chloride and potassium chloride are physiologic ions; no teratogenic effects are expected at therapeutic doses. Hypo- or hypernatremia/hyperkalemia may pose fetal risks indirectly. No specific trimester risks identified with proper electrolyte balance. |
| Fetal Monitoring | Monitor serum electrolytes (sodium, potassium, chloride), renal function, and fluid balance. In pregnancy, monitor for signs of fluid overload or electrolyte imbalances. Fetal monitoring indicated if maternal electrolyte disturbances occur. |
| Fertility Effects | No direct effects on fertility at therapeutic doses. Electrolyte imbalances, if severe, may indirectly impact reproductive function. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaHypernatremiaSevere metabolic acidosis with hyperkalemia
| Precautions | Risk of hyperkalemia, especially in patients with renal impairment, Risk of fluid overload in patients with congestive heart failure or renal insufficiency, Monitor serum electrolytes and renal function, Avoid rapid infusion to prevent hyperkalemia-induced cardiac arrest |
| Food/Dietary | Avoid high-potassium foods (e.g., bananas, oranges, tomatoes, potatoes, spinach, avocados, dried fruits) and potassium-containing salt substitutes unless directed by a physician. Dietary potassium intake should be consistent to avoid fluctuations. |
| Clinical Pearls | This solution is used for maintenance fluid therapy in patients with hypokalemia or to prevent potassium depletion, especially when NPO. Monitor serum potassium and renal function; contraindicated in severe renal impairment, hyperkalemia, or conditions with potassium retention. Infuse via central line if concentration exceeds 40 mEq/L. Use with caution in patients on ACE inhibitors, ARBs, or potassium-sparing diuretics. |
| Patient Advice | Report any muscle weakness, cramps, or irregular heartbeat immediately. · This medication contains potassium; do not take additional potassium supplements or salt substitutes without consulting your doctor. · Inform your healthcare provider about all medications you are taking, especially heart or blood pressure medicines. · You may experience burning at the IV site; report any pain, redness, or swelling. |
Loading safety data…